Results 141 to 150 of about 17,845 (225)

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model. [PDF]

Braz J Med Biol Res
Chege BM, Mwangi PW, Githinji CG, Bukachi F.   +3 more
europepmc   +1 more source

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort. [PDF]

J Antimicrob Chemother
Ciccullo A, Baldin G, Cervo A, Oreni L, Mazzitelli M, Gasparro G, Menozzi M, Cesaretti M, Bassani F, Lagi F, Lombardi F, Giacomelli A, Borghetti A, Fabbiani M, Rusconi S, Cattelan A, Antinori S, Mussini C, Di Giambenedetto S.   +18 more
europepmc   +1 more source

Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial. [PDF]

Clin Infect Dis
Brites C, Montaño-Castellon I, Arriaga MB, Marconi C, Mayoral R, Luz E, Figueredo CA, Fiuza BSD, Netto EM.   +8 more
europepmc   +1 more source

R263K-associated dolutegravir resistance on tenofovir, lamivudine and dolutegravir: Implications for earlier genotyping and regimen optimisation. [PDF]

S Afr J Infect Dis
Naidoo S.
europepmc   +1 more source

Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation. [PDF]

Ann Epidemiol
Zheng A, Fox MP, Greener R, Kileel EM, Bor J, Venter WD, Pisa PT, Murray EJ, Brennan AT, Maskew M.   +9 more
europepmc   +1 more source

Maintain, not obtain: rethinking HIV care in sub-Saharan Africa in the era of dolutegravir. [PDF]

Front Public Health
Perno CF, Orlando S, Majid NA, Sangare H, Luanga R, Roccucci M, Silaghi LA, Sidumo Z, Brambilla D, Ceffa S, Guidotti G, Ciccacci F.   +11 more
europepmc   +1 more source

Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]

Nat Commun
Català-Moll F, Blázquez-Bondia C, Farré-Badia J, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, Podzamczer D, Force L, Falcó V, Parera M, Casadellà M, Miró JM, Noguera-Julian M, Paredes R, ADVANZ-4 MISTRAL investigators.   +16 more
europepmc   +1 more source

Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing Surveillance. [PDF]

Adv Ther
Sebata A, Nagao T, Matsukawa T, Maeno Y, Suzuki M, Yoshikawa Y, Ibe S, Fukuda A, Wang D.   +8 more
europepmc   +1 more source

Mutation-Tolerant Inhibition of HIV-1 Integrase Strand Transfer by Secondary Metabolites from the Endophytic Fungus <i>Alternaria alternata</i> PO4PR2. [PDF]

Microorganisms
Mashabela N, Naidu D, Oduro-Kwateng E, Mkhwanazi NP.   +3 more
europepmc   +1 more source

Antiretroviral therapy switch among Medicare beneficiaries with HIV. [PDF]

J Manag Care Spec Pharm
Christoph MJ, Mordi U, Li S, Guo H, Gong T, Lim T, Park S, Zachry W, Tien PC.   +8 more
europepmc   +1 more source